Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T71164
(Former ID: TTDI01230)
|
|||||
| Target Name |
Ganglioside GD2 (GD2)
|
|||||
| Synonyms |
Ganglioside G2; GD2
Click to Show/Hide
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 10 Target-related Diseases | + | ||||
| 1 | Cervical cancer [ICD-11: 2C77] | |||||
| 2 | Lung cancer [ICD-11: 2C25] | |||||
| 3 | Adrenal cancer [ICD-11: 2D11] | |||||
| 4 | Brain cancer [ICD-11: 2A00] | |||||
| 5 | Colorectal cancer [ICD-11: 2B91] | |||||
| 6 | Osteosarcoma [ICD-11: 2B51] | |||||
| 7 | Pancreatic cancer [ICD-11: 2C10] | |||||
| 8 | Prostate cancer [ICD-11: 2C82] | |||||
| 9 | Sarcoma [ICD-11: 2A60-2C35] | |||||
| 10 | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 18 Clinical Trial Drugs | + | ||||
| 1 | Anti-GD2 CART | Drug Info | Phase 2 | Neuroblastoma | [1] | |
| 2 | APN301 | Drug Info | Phase 2 | Neuroblastoma | [2] | |
| 3 | Hu3F8 mAb | Drug Info | Phase 2 | Neuroblastoma | [3] | |
| 4 | Nivatrotamab | Drug Info | Phase 2 | Small-cell lung cancer | [4] | |
| 5 | 4SCAR-GD2 | Drug Info | Phase 1/2 | Tumour | [5] | |
| 6 | CAR-T cells targeting CD2 | Drug Info | Phase 1/2 | Cervical cancer | [6] | |
| 7 | CAR-T cells targeting GD2 | Drug Info | Phase 1/2 | Lung cancer | [7] | |
| 8 | CAR-T cells targeting GD2 | Drug Info | Phase 1/2 | Glioma | [8] | |
| 9 | GD2-CART01 | Drug Info | Phase 1/2 | Neuroblastoma | [9] | |
| 10 | Anti-GD2 T-cells (1RG-CART) | Drug Info | Phase 1 | Neuroblastoma | [10] | |
| 11 | Anti-GD2-CAR engineered T cells | Drug Info | Phase 1 | Neuroblastoma | [11] | |
| 12 | C7R-GD2.CART cells | Drug Info | Phase 1 | Neuroblastoma | [12] | |
| 13 | GD2 T cells | Drug Info | Phase 1 | Neuroblastoma | [13] | |
| 14 | IC9-GD2-CD28-OX40 | Drug Info | Phase 1 | Neuroblastoma | [14] | |
| 15 | IC9.GD2.CAR.IL-15 T-cells | Drug Info | Phase 1 | Neuroblastoma | [15] | |
| 16 | KUR-501 | Drug Info | Phase 1 | Neuroblastoma | [16] | |
| 17 | MVT-5873 | Drug Info | Phase 1 | Colorectal cancer | [3] | |
| 18 | GD2-targeted CAR-T cells | Drug Info | Clinical trial | Neuroblastoma | [17] | |
| Mode of Action | [+] 3 Modes of Action | + | ||||
| CAR-T-Cell-Therapy | [+] 13 CAR-T-Cell-Therapy drugs | + | ||||
| 1 | Anti-GD2 CART | Drug Info | [1] | |||
| 2 | 4SCAR-GD2 | Drug Info | [5] | |||
| 3 | CAR-T cells targeting CD2 | Drug Info | [6] | |||
| 4 | CAR-T cells targeting GD2 | Drug Info | [7], [19] | |||
| 5 | CAR-T cells targeting GD2 | Drug Info | [8] | |||
| 6 | GD2-CART01 | Drug Info | [9] | |||
| 7 | Anti-GD2 T-cells (1RG-CART) | Drug Info | [10] | |||
| 8 | Anti-GD2-CAR engineered T cells | Drug Info | [11] | |||
| 9 | C7R-GD2.CART cells | Drug Info | [12] | |||
| 10 | GD2 T cells | Drug Info | [13] | |||
| 11 | IC9-GD2-CD28-OX40 | Drug Info | [14] | |||
| 12 | IC9.GD2.CAR.IL-15 T-cells | Drug Info | [15] | |||
| 13 | GD2-targeted CAR-T cells | Drug Info | [17] | |||
| Inhibitor | [+] 2 Inhibitor drugs | + | ||||
| 1 | APN301 | Drug Info | [18] | |||
| 2 | Nivatrotamab | Drug Info | [4] | |||
| Modulator | [+] 1 Modulator drugs | + | ||||
| 1 | MVT-5873 | Drug Info | [3] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02765243) Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma | |||||
| REF 2 | Clinical pipeline report, company report or official report of Apeiron Biologics. | |||||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 4 | Clinical pipeline report, company report or official report of Y-mAbs Therapeutics. | |||||
| REF 5 | ClinicalTrials.gov (NCT02992210) Study on GD2 Positive Solid Tumors by 4SCAR-GD2 | |||||
| REF 6 | ClinicalTrials.gov (NCT03356795) Intervention of CAR-T Against Cervical Cancer | |||||
| REF 7 | ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer | |||||
| REF 8 | ClinicalTrials.gov (NCT03252171) CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients | |||||
| REF 9 | ClinicalTrials.gov (NCT03373097) Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma | |||||
| REF 10 | ClinicalTrials.gov (NCT02761915) A Cancer Research UK Trial of Anti-GD2 T-cells (1RG-CART) | |||||
| REF 11 | ClinicalTrials.gov (NCT02107963) A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors | |||||
| REF 12 | ClinicalTrials.gov (NCT03635632) C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma (GAIL-N) | |||||
| REF 13 | ClinicalTrials.gov (NCT01953900) iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma | |||||
| REF 14 | ClinicalTrials.gov (NCT01822652) 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN | |||||
| REF 15 | ClinicalTrials.gov (NCT03721068) Phase I Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma | |||||
| REF 16 | Clinical pipeline report, company report or official report of Kuur Therapeutics. | |||||
| REF 17 | ClinicalTrials.gov (NCT02919046) Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children | |||||
| REF 18 | Clinical pipeline report, company report or official report of Apeiron Biologics. | |||||
| REF 19 | ClinicalTrials.gov (NCT03170141) Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.